METASTRON
LOE ApproachingNDAINJECTIONINJECTABLEPriority Review
Approved
Jun 1993
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 22h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
METASTRON is an injectable NDA-approved pharmaceutical product developed by Q BioMed with a regulatory history dating to 1993. The specific mechanism of action, indications, and pharmacologic class are not publicly detailed in available data. The product is positioned as an injection-based therapeutic with established market presence.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%), indicating contracting commercial teams and transition focus toward pipeline development.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on METASTRON presents a challenging career trajectory given the LOE-approaching lifecycle stage and absence of linked job openings. Limited commercial momentum and clinical activity suggest this product is in managed decline, reducing growth opportunities and team expansion prospects.
Company
Worked on METASTRON at Q BioMed? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.